elcuidadodelasalude.org



Agilent Technologies introduces SureSelect Human All Exon v2 Target Enrichment kit for cancer assay

February 15, 2016

99.01 percent of human exons defined by the NCBI Consensus CDS Database from September 2009; 93.29 percent of RefSeq genes; 95.07 percent of RefSeq transcripts from June 2010; and 90 percent of miRNA in miRBase v14.

The kit targets just over 38 Mb of the human genome in a single tube reaction. In addition to the new content, teams at the Broad Institute and Agilent have carefully re-balanced the mixture of probes to maximize capture efficiency and uniformity across the exome.

Agilent's SureSelect Target Enrichment System offers the broadest range of target enrichment products and the most highly optimized protocols for a diverse set of sequencing methods and platforms. There are now 15 products in the SureSelect portfolio, with many more in development. SureSelect products are available for enrichment of target sizes ranging from smaller than 200 Kb to more than 50 Mb in a single tube. Protocols now support Illumina end sequencing, paired-end sequencing and indexing protocols in addition to fragment library format, paired-end sequencing and barcoding on the SOLiD System.

Users of Agilent's eArray xD desktop design tool can improve the efficiency of their research by easily designing custom products to target any genome of interest, all in a single tube. Agilent also offers the eArray online design tool, enabling users to customize pre-defined SureSelect kits such as the SureSelect Human All Exon series of products.

Source : Agilent Technologies Inc.